Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

Antiviral Research

Volumn 77, Issue 1, 2008, Pages 56-63

  Korba, Brent E ^a   Montero, Abigail B ^a   Farrar, Kristine ^a   Gaye, Karen ^a   Mukerjee, Sampa ^a   Ayers, Marc S ^b   Rossignol, Jean François ^b,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Romark Institute for Medical Research   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Hepatitis B virus; Hepatitis C virus; Nitazoxanide; Thiazolides

Indexed keywords

2' C METHYLCYTIDINE; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NITAZOXANIDE; RECOMBINANT ALPHA2B INTERFERON; RM 4832; RM 4848; RM 4850; RM 4851; RM 4852; RM 4863; TELAPREVIR; THIAZOLE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; REPLICON; RNA TRANSCRIPTION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS ANTIGENS; HEPATITIS B VIRUS; HUMANS; MUTATION; SERUM; THIAZOLES; VIRUS REPLICATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; LETTUCE MOSAIC VIRUS; PROTOZOA;

EID: 37449014458     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.08.005     Document Type: Article

References (36)

1. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., and Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
2. Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., and Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360 (2002) 1375-1380
3. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., and Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
4. Belen'kii M.S., and Schinazi R.F. Multiple drug effect analysis with confidence interval. Antivir. Res. 25 (1994) 1-11
5. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
6. Blight K.J., McKeating J.A., Marcotrigiano J., and Rice C.M. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77 (2003) 3181-3190
7. Broekhuysen J., Stockis A., Lins R.L., De Graeve J., and Rossignol J.F. Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38 (2000) 387-394
8. Chen S.L., and Morgan T.R. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 3 (2006) 47-52
9. Courcambeck J., Bouzidi M., Perbost R., Jouirou B., Amrani N., Cacoub P., Pèpe G., Sabatier J.M., and Halfon P. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir. Ther. 11 (2006) 847-855
10. Fox L.M., and Saravolatz L.D. Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40 (2005) 1173-1180
11. Hoffman P.S., Sisson G., Croxen M.A., Welch K., Harman W.D., Cremades N., and Morash M.G. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori and selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 51 (2007) 868-876
12. Iyer R.P., Jin Y., Roland A., Morrey J.D., Mounir S., and Korba B. Phosphorothioate di- and tri-nucleotides as a novel class of anti-HBV agents. Antivir. Agents Chemother. 48 (2004) 2199-2205
13. Korba B. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res. 29 (1996) 49-51
14. Korba B.E., Cote P.J., Menne S., Toshkov I., Baldwin B.H., Wells F.V., Tennant B.C., and Gerin J.L. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir. Ther. 9 (2004) 937-952
15. Korba B.E., and Gerin J.L. Use of a standardized cell culture assay to determine activities of nucleoside analogs against hepatitis b virus replication. Antivir. Res. 19 (1992) 55-70
16. Korba B.E., and Gerin J.L. Antisense oligonucleotides are effective inhibitors of hepatitis b virus replication in vitro. Antivir. Res. 28 (1995) 225-242
17. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. 11 (2004) 97-107
18. Locarnini S. Molecular virology of hepatitis B virus. Semin. Liver Dis. 24 Suppl. 1 (2004) 3-10
19. Menne S., Roneker C.A., Tennant B.C., Korba B.E., Gerin J.L., and Cote P.J. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 45 (2002) 237-250
20. Musher D.M., Logan N., Hamill R.J., DuPont H.L., Lentnek A., Gupta A., and Rossignol J.F. Nitazoxanide in the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43 (2006) 421-427
21. Okuse C., Rinaudo J.A., Farrar K., Wells F., and Korba B.E. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antivir. Res. 65 (2005) 23-34
22. Ortiz J.J., Ayoub A., Gargala G., Chegne N.L., and Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis from northern Peru. Aliment. Pharmacol. Ther. 15 (2001) 1409-1415
23. Pankuch G.A., and Appelbaum P.C. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic bacteria. Antimicrob. Agents Chemother. 50 (2006) 112-117
24. Pierra C., Benzaria S., Amador A., Moussa A., Mathieu S., Storer R., and Gosselin G. NM283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 24 (2005) 767-770
25. Rossignol J.F. Nitazoxanide in the treatment of AIDS-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment. Pharmacol. Ther. 24 (2006) 887-894
26. Rossignol J.F., Abu-Zekry M., Hussein A., and Santoro M.G. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 368 (2006) 124-129
27. Rossignol J.F., Ayoub A., and Ayers M.S. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a double blind placebo controlled study of nitazoxanide. J. Infect. Dis. 184 (2001) 381-384
28. Rossignol J.F., and El-Gohary Y. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind, placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 24 (2006) 1423-1430
29. Rossignol J.F., Kabil S.M., El-Gohary Y., and Younis A.M. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium spp. Clin. Gastroenterol. Hepatol. 4 (2006) 320-324
30. Rossignol J.F., Kabil S.M., Said M., Samir H., and Younis A. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol. 3 (2005) 987-991
31. Sells M.A., Zelent A.Z., Shvartsman M., and Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62 (1988) 2836-2844
32. Stockis A., De Bruyn S., Gengler C., and Rosillon D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1.0 g b.i.d. Int. J. Clin. Pharmacol. Ther. 40 (2002) 221-227
33. Tomei L., Altamura S., Paonessa G., De Francesco R., and Migliaccio G. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antivir. Chem. Chemother. 16 (2005) 225-245
34. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antivir. Res. 70 (2006) 28-38
35. Wong S.N., and Lok A.S. Update on viral hepatitis: 2005. Curr. Opin. Gastroenterol. 22 (2006) 241-247
36. Yim H.J., Hussain M., Liu Y., Wong S.N., Fung S.K., and Lok A.S. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712